![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
PiFLU (favipiravir), is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase, which is indicated for the treatment of COVID-19 infection.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: PiFlu
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020